Equities
Health CareHealth Care Providers
  • Price (NZD)5.05
  • Today's Change0.05 / 1.00%
  • Shares traded770.52k
  • 1 Year change-4.54%
  • Beta1.8535
Data delayed at least 20 minutes, as of Nov 22 2024 04:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NZDIncome statement in NZDView more

Year on year Ryman Healthcare Ltd had net income fall -98.15% from 257.84m to 4.78m despite a 20.83% increase in revenues from 570.98m to 689.89m.
Gross margin--
Net profit margin0.69%
Operating margin-39.69%
Return on assets0.04%
Return on equity0.11%
Return on investment0.07%
More ▼

Cash flow in NZDView more

In 2024, Ryman Healthcare Ltd increased its cash reserves by 49.97%, or 13.93m. The company earned 658.48m from its operations for a Cash Flow Margin of 95.45%. In addition the company generated 197.50m cash from financing while 842.05m was spent on investing.
Cash flow per share0.0706
Price/Cash flow per share68.65
Book value per share6.42
Tangible book value per share6.30
More ▼

Balance sheet in NZDView more

Ryman Healthcare Ltd has a Debt to Total Capital ratio of 36.77%, a lower figure than the previous year's 50.27%.
Current ratio--
Quick ratio--
Total debt/total equity0.5816
Total debt/total capital0.3677
More ▼

Growth rates in NZD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -100.00% and -98.00%, respectively. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)0.85%
Div growth rate (5 year)--
Payout ratio (TTM)0.00%
EPS growth(5 years)-59.21
EPS (TTM) vs
TTM 1 year ago
-98.03
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.